MaxCyte Inc (MXCT)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $122.87M
Last updated: Nov 17, 2026 at 4:15 PM ET
MaxCyte Inc (MXCT) Statistics
MaxCyte (MXCT) has a market cap of $122.87M and an enterprise value of $109.50M. It kept -81.40% of revenue as net income over the last 12 months. Its share count is down 2.88% from a year earlier.
Total Valuation
Enterprise value is 10.88% below the market cap, as cash exceeds debt.
| Market Cap | $122.87M |
|---|---|
| Enterprise Value | $109.50M |
| Latest price (Nov 17, 2026) | $1.17 |
Key Dates
The next earnings report is expected on Mar 12, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 12, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 10, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 3.5x and 0.8x. Its year-end P/S ranged from 4.3x to 27.5x from 2020 to 2025.
| P/S Ratio | 3.5x |
|---|---|
| Forward P/S | 3.5x |
| P/B Ratio | 0.8x |
| P/TBV Ratio | 0.8x |
Price Statistics
The stock is down 25.95% over 52 weeks and trades 6.40% below its 50-day average.
| Beta (1Y) | 1.43 |
|---|---|
| 52-Week Change | -25.95% |
| 1-Month Change | -10.00% |
| 3-Month Change | -15.83% |
| 6-Month Change | +12.50% |
| 5-Year Change | -85.85% |
| Total Return (1Y) | -25.95% |
| Total Return (3Y CAGR) | -34.42% |
| Total Return (5Y CAGR) | -37.61% |
| Return vs SPY (1Y) | -43.14% |
| Max Drawdown (1Y) | -61.58% |
| Max Drawdown (3Y) | -87.42% |
| Sharpe Ratio (1Y) | -0.53 |
| Correlation with SPY (1Y) | 0.28 |
| 50-Day Average | $1.25 |
| 200-Day Average | $1.07 |
| 52-Week Range | $0.64 to $1.80 |
| RSI (14 Days) | 42.0 |
| Average Volume (20 Days) | 1.47M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 7.83x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 7.83x |
|---|---|
| Quick Ratio | 7.37x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -18.54% over the last 12 months, against a 5-year average of -15.76%.
| Return on Equity (ROE) | -18.54% |
|---|---|
| Return on Assets (ROA) | -15.33% |
| ROE (5Y Average) | -15.76% |
| ROA (5Y Average) | -13.65% |
| ROIC (5Y Average) | -23.91% |
| Asset Turnover | 0.17x |
| Inventory Turnover | 0.86x |
| Receivables Turnover | 4.30x |
| Cash Conversion Cycle | 431 days |
Scores
MXCT has an Altman Z-Score of 0.45, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 0.45 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 2 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue of $34.37M over the last 12 months is down 0.13% from the 12 months before.
| Revenue | $34.37M |
|---|---|
| Revenue Growth (YoY) | -0.13% |
| Gross Profit | $27.84M |
| Operating Income | -$33.68M |
| Pretax Income | -$27.98M |
| Net Income | -$27.98M |
| Reported EPS (TTM) | -$0.23 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 82.71% of the $182.48M in total assets.
| Cash and Equivalents | $13.37M |
|---|---|
| Total Debt | $0 |
| Net Cash | $13.37M |
| Net Cash Per Share | $0.13 |
| Working Capital | $108.75M |
| Shareholder Equity | $150.93M |
| Book Value Per Share | $1.46 |
| Tangible Book Value | $150.18M |
| Tangible Book Per Share | $1.45 |
| Total Assets | $182.48M |
| Total Liabilities | $31.55M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $424.00K of capital spending, operating cash flow left -$21.45M of free cash flow.
| Operating Cash Flow | -$21.02M |
|---|---|
| Capital Expenditures | $424.00K |
| Free Cash Flow | -$21.45M |
| FCF Per Share | -$0.21 |
| Depreciation and Amortization | $4.78M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -97.99%.
| Gross Margin | 80.98% |
|---|---|
| Operating Margin | -97.99% |
| Pretax Margin | -81.40% |
| Net Margin | -81.40% |
| FCF Margin | -62.40% |
| Gross Margin (5Y Average) | 85.80% |
| Net Margin (5Y Average) | -88.57% |
Growth
Revenue fell 9.30% a year over 3 years.
| Revenue Growth (3Y CAGR) | -9.30% |
|---|---|
| Revenue Growth (5Y CAGR) | +4.76% |
| Book Value Per Share Growth (2Y CAGR) | -15.16% |
| Tangible Book Per Share Growth (2Y CAGR) | -15.32% |
Dividends and Yields
MXCT does not pay a dividend. Its free cash flow yield is -17.71%.
| FCF Yield | -17.71% |
|---|---|
| Buyback Yield | 3.25% |
| Shareholder Yield | 3.25% |
Peer Position
Against 12 similar companies, MXCT has the 3rd highest P/S.
P/S RatioPeer median 2.1x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +14.75%
| P/S Ratio | 3.5x vs 2.1x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | -0.13% vs +14.75% median |
Analyst Forecast
Consensus estimates put revenue growth at 15.00% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +15.00% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About MXCT
What is MXCT's market cap?
MaxCyte has a market cap of $122.87M. Its enterprise value, which adds debt and subtracts cash, is $109.50M.
How many shares of MXCT are outstanding?
MaxCyte has 103.54M shares outstanding. The count is down 2.88% from a year earlier.
Does MXCT pay a dividend?
No. MaxCyte does not pay a dividend.
How much debt does MXCT have?
MaxCyte has $0 of total debt and $13.37M of cash and equivalents, a net cash position of $13.37M.
MXCT pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts